Our genome-wide association study of celiac disease previously identified risk variants in the IL2-IL21 region. To identify additional risk variants, we genotyped 1,020 of the most strongly associated non-HLA markers in an additional 1,643 cases and 3,406 controls. Through joint analysis including the genome-wide association study data (767 cases, 1,422 controls), we identified seven previously unknown risk regions (P o 5 Â 10 À7 ). Six regions harbor genes controlling immune responses, including CCR3, IL12A, IL18RAP, RGS1, SH2B3 (nsSNP rs3184504) and TAGAP. Whole-blood IL18RAP mRNA expression correlated with IL18RAP genotype. Type 1 diabetes and celiac disease share HLA-DQ, IL2-IL21, CCR3 and SH2B3 risk regions. Thus, this extensive genome-wide association follow-up study has identified additional celiac disease risk variants in relevant biological pathways.
Celiac disease is common in populations of European ancestry, with a prevalence of approximately 1% 1 . HLA-DQ2-or HLA-DQ8-restricted T-cell responses to dietary proteins in wheat, rye and barley lead to small-intestinal inflammation and intestinal villous atrophy with consequent clinical features. Recent immunological advances have identified dominant epitopes, established the role of tissue transglutaminase and determined the crystal structures of HLA-DQ molecules binding wheat peptides 1 . However, the primary factors (both environmental and genetic) predisposing to disease in the B30% of the population carrying susceptible HLA-DQ types are mostly unknown.
To identify additional genes associated with celiac disease susceptibility, we recently tested 310,605 SNPs in a genome-wide association study of 778 celiac cases and 1,422 population controls from the UK (UKGWAS), using the Illumina HumanHap300 BeadChip 2 . The only SNP outside the HLA region showing genome-wide significance was rs13119723 on 4q27, located in a B500-kb block of linkage disequilibrium (LD) containing the IL2 and IL21 genes 2 . Independent replication of SNPs from the IL2-IL21 region was established in both Dutch and Irish collections of celiac cases and controls. Using the current markers, we estimate that the IL2-IL21 region explains o1% of the increased familial risk of celiac disease, suggesting that there are additional unidentified susceptibility genes. As we observed a greater number of significantly associated SNPs in the UKGWAS than would be expected by chance, we proceeded to study 41,000 of the most significant UKGWAS association results in a further 1,643 celiac cases and 3,406 controls from three independent European celiac disease collections. This two-stage strategy, involving a joint analysis of all data, substantially reduces the genotyping requirements, as it does not require carrying out genome-wide genotyping on all samples, and has been shown to maintain sufficient statistical power 3 .
RESULTS

Overview of association results
We initially selected 1,164 non-HLA SNPs from the UKGWAS for follow up, comprising 1,088 single SNPs with association results of P o 0.00275 and 76 additional nonsynonymous SNPs (nsSNP) with association results between P Z 0.00275 and P o 0.01. After exclusion of SNPs unlikely to be successful on the basis of Illumina GoldenGate assay design criteria, or by inspection of actual genotype clusters, we analyzed a total of 1,025 SNPs in follow-up collections. These collections comprised celiac cases and controls of Northern European origin and of similar phenotypes to the UKGWAS samples. We did not genotype additional markers from candidate regions, as our primary aim was to identify additional risk regions rather than to precisely localize the actual causal genetic variants 4, 5 . This design represents an unbiased search of the genome for susceptibility variants. The markers included eight SNPs from the IL2-IL21 region that were reported to be associated with celiac disease in our previous study 2 ; we also included five SNPs to identify HLA-DQ2 or HLA-DQ8 status 6 . We excluded samples failing quality control criteria (see Methods), and analyzed 719 cases and 1,561 population controls from the UK (UK2 collection), 416 cases and 957 bloodbank controls from Ireland (IRISH), and 508 cases and 888 bloodbank controls from the Netherlands (DUTCH).
Observed association statistics for the UKGWAS SNPs in the followup collections deviated markedly from expected findings (Fig. 1) . We report 21 non-HLA SNPs from eight distinct chromosomal regions meeting a genome-wide significance threshold in all 7,238 samples of P overall o5 Â 10 À7 (Table 1) . Results from the Wellcome Trust Case Control Consortium (WTCCC) 7 and other recent GWA studies have shown that most markers at a P o 5 Â 10 À7 'genome-wide' significance level will be true findings, although independent replication by other investigators is necessary for definitive validation. Only one of these eight regions, the IL2-IL21 region 2 , has been previously reported to be associated with celiac disease. Breslow-Day tests were nonsignificant for each of the eight regions, implying consistent effect sizes and direction across the four collections and accuracy of the reported Cochran-Mantel-Haenszel test odds ratios. The observation of generally weaker association evidence in the IRISH dataset (Supplementary Data 1 online) is therefore likely to be a reflection of the smaller sample size of this collection, rather than ethnic heterogeneity.
We did not observe any evidence for gene-gene interactions (departure from log-additive effects) between these regions, nor between the HLA and these regions. Association statistics, linkage disequilibrium (LD) plots and Ensembl genes for each of the eight regions are shown in Table 1 and Figure 2 ; more detailed statistics for all markers in each collection are shown in Supplementary Data 1.
The association of HLA-DQ variants with celiac disease reflects the ability of antigen-presenting cells to present toxic cereal epitopes to T cells. Notably, seven of the eight identified non-HLA regions also contain biologically plausible candidate genes involved in the immune response.
We inspected the data for possible bias due to population differences between cases and controls, genotyping artefacts, missing genotype data or other factors 8 . The overall genotype call rate across all samples and SNPs was high at 99.94% (details for each marker listed in Supplementary Data 1). Inspection of cluster plots for the most associated SNPs from each of the eight non-HLA regions associated with celiac disease ( Supplementary Fig. 1 online) , consistent findings from two assay chemistries (Infinium and GoldenGate) in the UK populations and multiple associated SNPs for some regions suggested that the results were not laboratory-generated false-positive findings. We assessed the median distribution of test statistics using genomic control 9 (l GC ¼ 1.0 indicates a null distribution with no inflation of test statistics). In the full UKGWAS genome-wide association scan dataset (using 767 cases with no first-degree relation and 1,422 controls genotyped for 307,411 non-HLA SNPs), there was minimal evidence for inflation of test statistics (l GC ¼ 1.03). In the UK2, IRISH and DUTCH follow-up samples, genotyped for 1,020 non-HLA SNPs, there was also little evidence for inflation (l GC ¼ 1.02). When we also excluded 28 SNPs mapping to the eight non-HLA celiac disease-associated regions, there was no evidence for test statistic bias (l GC ¼ 1.00) in the follow-up samples, and the residual Q-Q plot showed little deviation from expected results (Fig. 1b) . Furthermore, when we used an alternative principal components approach, each of the eight non-HLA regions again met the genome-wide significance threshold (P overall o5 Â 10 À7 ) when corrected by EIGENSTRAT analysis (Supplementary Data 1) .
We correlated cis gene expression in whole-blood RNA samples (n ¼ 109) with SNPs from the eight non-HLA celiac-associated regions to test for possible functional effects of these markers. Eight putative candidate genes from the regions were expressed above background levels in these samples. We analyzed 14 pairs of SNPs and expressed gene probes (Supplementary Data 2 online). We also assessed tissue and cell type expression for putative candidate genes Table 1 with P overall o5 Â 10 À7 in all samples including UKGWAS. Straight line indicates expected results under null hypothesis. (b) Q-Q plot of residual association results (Cochran-MantelHaenszel test) for 992 non-HLA SNPs, excluding 28 SNPs mapping to the eight celiac disease-associated regions described in Table 1 , in UK2, IRISH and DUTCH follow-up samples. Cochran-Mantel-Haenszel association analysis of 1,020 SNPs (excluding HLA region). SNPs with P overall o5 Â 10 -7 (the WTCCC threshold for reporting possible associations 7 ) are shown. Association statistics are reported for 21 SNPs from eight regions, including the previously reported IL2-IL21 region. Chromosomal positions are based on NCBI Build 36 coordinates. Data from the UKGWAS were re-analyzed with removal of a small number of first-degree relatives, in contrast to our previous study 2 .
a Odds ratios for the UKGWAS and overall study are reported in Supplementary Data 1. b Named genes either map, or are adjacent, to the same strong LD block as associated SNPs, or the SNPs physically map within the gene. Causality is not proven. c rs3184504 is a nonsynonymous SNP in SH2B3 (R262W). 
A R T I C L E S
from each region on the basis of published literature and the GNF SymAtlas database 10 . We analyzed gene expression in small-intestinal tissue (where celiac disease manifests) from healthy controls and from treated and untreated individuals with celiac disease. We summarize results for each region below.
4q27
A previously identified SNP (rs6822844) 2 , located B24 kb 3¢ of IL21, showed the strongest association with celiac disease in the current study (P overall ¼ 2.82 Â 10 À13 ). Independent replication, with the same allele and direction, of our previous report 2 is provided by the UK2 collection (Supplementary Data 1, rs6822844 P UK2 ¼ 0.0017). This SNP is among a cluster of eight associated SNPs that are in a block of strong linkage disequilibrium containing four genes (KIAA1109-ADAD1-IL2-IL21). Both IL2 and IL21 are strong candidate genes because of their role in T-cell activation 2, 11, 12 . A SNP allele from this region was also reported in a recent GWAS for type 1 diabetes (conferring susceptibility) and was found to be associated with Graves' disease (conferring reduced risk) 11 . A further Dutch study suggested association of rs6822844 with type 1 diabetes and rheumatoid arthritis, in the same direction as the celiac disease data 13 . These findings suggest that the 4q27 region might represent a general autoimmune disease risk locus, although the exact nature of the effects, and whether they are due to one or multiple causal variants, is currently unclear.
1q31
The most significant SNP outside the HLA and IL2-IL21 regions is rs2816316 (P overall ¼ 2.58 Â 10 À11 ), located within a B70-kb LD block containing the gene RGS1 (regulator of G-protein signaling 1). rs2816316 maps 8 kb distal to the 5¢ end of RGS1. RGS family genes attenuate the signaling activity of G proteins by acting as GTPase activating proteins. RGS1 acts to regulate chemokine receptor signaling and is known to be involved in B-cell activation and proliferation. Rgs1 À/À mice have enhanced B-cell movement into and out of lymph nodes 14 and heightened dendritic cell migratory response to chemokines 15 . We found RGS1 to be expressed in human smallintestinal biopsies ( Supplementary Fig. 2 online) . Notably, we previously observed Rgs1 to be strongly expressed in murine intestinal intra-epithelial lymphocytes 16 , and we now confirm that T-cell Rgs1 expression seems to be specific to the intestinal intra-epithelial lymphocyte compartment and is not found in conventional splenic or thymic ab T cells ( Supplementary Fig. 3 online) . Intestinal intraepithelial lymphocytes have a key role in epithelial cell death and the development of villous atrophy in celiac disease 17 .
2q11-2q12
Two associated SNPs, rs917997 (P overall ¼ 8.49 Â 10 À10 ) and rs13015714 (both in LD, r 2 ¼ 0.95 in UKGWAS controls), map to a B400-kb LD block. Of note, in the WTCCC GWAS 7 , Crohn's disease shows modest association with this region (proxy SNP for rs917997, P B10 À4 , Supplementary Data 3 online). This LD block contains four genes, two of which encode the receptor for the IL-18 protein (IL18RAP and IL18R1) . The IL-18 pathway is highly relevant, as mature IL-18 induces T cells to synthesize interferon-g, a key cytokine involved in the mucosal inflammation of celiac disease. IL-18 binds to targeted cells through a receptor comprising an a chain (IL18Ra, IL18R1) and a b chain (IL18Rb, AcPL, IL18RAP). Mature IL-18 is expressed in the intestinal mucosa of active, treated and latent celiac cases, but not in healthy controls 18 . IL18RAP is strongly expressed in unstimulated T cells and natural killer cells (GNF SymAtlas 10 ) and is expressed in small-intestinal biopsies ( Supplementary Fig. 2 ). We observed a large cis effect (ANOVA P ¼ 3.2 Â 10 À5 ) of rs917997 genotypes on the level of IL18RAP mRNA expression in whole blood from treated individuals with celiac disease (Fig. 3) , accounting for 16.1% of the population variance in IL18RAP expression. We observed a significant allele dosage effect on expression (post hoc regression testing for linear trend P o 0.0001). Individuals homozygous for the minor rs917997 A allele (which is more common in individuals with celiac disease than in control subjects) expressed the lowest levels of IL18RAP mRNA, heterozygotes expressed intermediate levels and G-allele homozygotes expressed the highest levels.
We sequenced the coding regions of IL18RAP in 23 individuals with celiac disease and eight control individuals, and found 19 variants, 17 of which were already in dbSNP. No variants (dbSNP or from resequencing) map to the region of the Illumina IL18RAP expression probe. None of the variants were predicted to have functional consequences. One newly identified variant (1210+17A4G) was observed in a single control, and the other newly identified variant (1384+70_1384+71insT) was found in two individuals with celiac disease. 3p21 SNP rs6441961 (P overall ¼ 3.14 Â 10 À7 ) maps within a large cluster of chemokine receptor genes on 3p21, including CCR1, CCR2, CCRL2, CCR3, CCR5 and XCR1. rs6441961 lies 44 kb 3¢ of the nearest gene (CCR3). LD-block definition is hampered by poor HapMap coverage of this region due to structural variation 19 . Chemokines and their receptors are critical for the recruitment of effector immune cells to the site of inflammation. In the WTCCC GWAS 7 , type 1 diabetes shows modest association in the same direction with the same allele of SNP rs6441961 (P B10 À5 , Supplementary Data 3), suggesting a possible common mechanism shared by both immune-mediated diseases.
3q25-3q26
Two SNPs (rs17810546, rs9811792) in a B70-kb LD block show strong association with celiac disease (rs17810546 P overall ¼ 1.07 Â 10 À9 ). This region is immediately 5¢ of IL12A (interleukin-12 A). Notably, the two associated SNPs (r 2 ¼ 0.19 in UKGWAS controls) may represent independent association signals. SNP rs17810546 also shows modest correlation with SNPs in both IL12A and SCHIP1 (schwannomin interacting protein 1). IL12A encodes the IL12p35 subunit, which together with IL12p40 forms IL12p70, the heterodimeric IL-12 cytokine that has a broad range of biological activities on T and natural killer cells. IL-12 induces interferon-g-secreting Th1 cells, one of the immunological hallmarks of celiac disease. Multiple correlated SNPs (rs1464510 P overall ¼ 5.33 Â 10 À9 ) within a B70-kb LD block show association with celiac disease. This block is either 5¢ of the RefSeq gene LPP or intronic for other possible isoforms of LPP. The LPP gene shows very high expression in the small intestine ( Supplementary Fig. 2 ) and may have a structural role at sites of cell adhesion in maintaining cell shape and motility. Relatively little is known about LPP, and how genetic variation in this region might predispose to celiac disease is unclear.
6q25 SNP rs1738074 (P overall ¼ 6.71 Â 10 À8 ) on chromosome 6q25.3 maps to a B200-kb LD block containing TAGAP (T-cell activation GTPase activating protein), itself within a larger region of weaker LD containing RSPH3 (radial spokehead-like 3). TAGAP is expressed in activated T cells 20 , has three isoforms and is a Rho GTPase-activating protein important for modulating cytoskeletal changes, although little is known about its role in immune function.
12q24
Association signals arise from two correlated SNPs, rs653178 (P overall ¼ 8 Â 10 À8 ) and rs3184504 (r 2 ¼ 0.99 in UKGWAS controls). These markers map in the vicinity of SH2B3 (also known as LNK) and ATXN2; modest LD is seen over a broader region of B1 Mb containing multiple other genes. Strong association with type 1 diabetes is reported in this region, with rs3184504 (same allele and direction as celiac disease) entirely accounting for the association signal 11 . SH2B3 is strongly expressed in monocytes and dendritic cells, as well as to a lesser extent in resting B, T and natural killer cells (GNF SymAtlas 10 ). We found SH2B3 to be strongly expressed in the small intestine; higher expression in inflamed celiac biopsies may reflect leukocyte recruitment and activation ( Supplementary Fig. 2 ). rs3184504 is a nonsynonymous SNP in exon 3 of SH2B3, leading to a R262W amino acid change in the pleckstrin homology domain. This domain may be important in plasma membrane targeting. SH2B3 regulates T-cell receptor, growth factor and cytokine receptor-mediated signaling implicated in leukocyte and myeloid cell homeostasis 21, 22 . Sh2b3 À/À mice have increased responses to multiple cytokines 22 .
DISCUSSION
We previously carried out the first genome-wide association study of celiac disease and reported risk variants in the IL2-IL21 region contributing to disease susceptibility 2 . Other than IL2-IL21, only the well-recognized HLA-DQ region has been convincingly associated with celiac disease. Our current study assessed 1,020 top celiac GWAS SNP associations (including all markers with P o 0.00275 in the original study) in further follow-up samples and identified seven previously unknown regions contributing significantly toward celiac disease risk. Our strategy of testing a further set of nsSNPs selected on the basis of a lower significance threshold did not yield any additional findings. The most significant SNPs for each of the seven regions are common (minor allele frequency 40.1); however, the observed effect sizes in the follow-up collections are modest (with increased or decreased odds ratios between 1.19 and 1.34). These are very similar magnitudes of effect sizes to other markers recently identified for other common diseases 7, 11, 23 . We note that the markers selected for the Illumina Hap300 are mainly tag SNPs, possibly mapping to relatively large regions of LD, and are unlikely to be the causal variants. As none of the variants are expected to be causal (although rs3184504 might be an exception), these odds ratios may underestimate the true effect sizes.
These seven newly identified regions, together with IL2-IL21, explain B3-4% of the heritability of celiac disease. These estimates are based on the current markers and may be higher once the causal variants from each region are known. Consideration of the current findings, together with the strong risk attributed by HLA-DQ2 and HLA-DQ8 (in this study estimated to be B35%), suggests that many further regions associated with celiac disease susceptibility remain undetected. Additional regions might be identified by carrying out genome-wide association on a larger sample size and in other collections (and possibly at higher marker density). As not all disease susceptibility variants may be common SNPs, future attempts should also focus on rare variants and copy number polymorphisms. The pathways identified in this study may provide a good starting point.
Celiac disease is considered a Th1-mediated disorder in which HLA-DQ2 and HLA-DQ8 have an important role in presenting wheat (also rye and barley) peptides to CD4 + T cells in the lamina propria. Tissue transglutaminase deamidation of immunodominant wheat peptides leads to higher DQ2 affinity, and tissue transglutaminase is the major target of the autoantibody response in celiac disease. Although we have not proved causality for any SNP variant, nor precisely identified the biologically important gene from each of the newly identified regions, it is notable that candidate genes mapping to seven of the eight non-HLA regions have clear functions in the immune response. Specific pathways include chemokines, cytokines and B-and T-cell activation. The regions that we have identified suggest that there are critical steps required for progression toward full-blown celiac disease. These newly identified susceptibility genes may also partly explain why only a minority of HLA-DQ2 (or HLA-DQ8) positive individuals develop celiac disease, although (unknown) environmental factors are likely to play a role.
We provide plausible biological mechanisms for variants from two of the celiac disease-associated regions: for SH2B3, a nonsynonymous SNP in a functional domain, and for IL18RAP, an effect of SNP genotype on mRNA expression. The IL18RAP findings, in which the rs917997 minor allele is more common in celiac subjects than in controls and associated with lower IL18RAP mRNA expression, might suggest that leucocytes from individuals with celiac disease have reduced signaling in response to IL-18 and generate less interferon-g. This is somewhat counterintuitive, given the observed intestinal inflammation and high mucosal interferon-g levels in celiac disease. However, similarly counterintuitive situations are observed in (i) Crohn's disease, where disease-associated NOD2 (CARD15) variants are loss-of-function mutations (that is, less NF-kB activation in response to NOD2 agonist), yet where there is excessive intestinal inflammation 24 , and (ii) autoimmune diseases, where a gain-offunction PTPN22 variant leads to reduced B and T cell receptormediated signaling, yet where there is an observed excessive systemic inflammatory response in a variety of autoimmune conditions 25 . Our understanding of the complex biology of celiac disease, including that of regulatory T cells, remains incomplete.
It has been suggested that common pathogenic effector pathways exist between HLA-associated autoimmune disorders such as celiac disease, type 1 diabetes and rheumatoid arthritis. In these conditions, the key elements regulating the attack or destruction of tissues or organ systems by an inappropriate or excessive immune response include genetic factors, innate and adaptive immune regulation, and triggering environmental factors such as infections or dietary components. T-cell activation is a generic process playing a role in all autoimmune disorders. Published data suggests that IL2-IL21 risk variants (not necessarily the same alleles) may predispose to celiac disease, type 1 diabetes, Graves' disease and rheumatoid arthritis 11, 13 .
Consideration of the current regions associated with celiac disease and the WTCCC seven disease GWAS dataset 7 suggests possible common mechanisms between celiac disease and type 1 diabetes at the SH2B3 region and the 3p21 CCR gene region, and between celiac disease and Crohn's disease at the IL18RAP region. It will be interesting to investigate the current regions associated with celiac disease in studies of other autoimmune disorders and to dissect separate disease-specific genes from more generic genes. This information may be useful to unravel the pathological mechanisms of autoimmune diseases and may provide targets for intervention.
Our results have considerably enhanced our understanding of celiac disease pathogenesis. The identification of risk factors for celiac disease that point toward involvement of genes implicated in various aspects of immunity further highlights the importance of such responses for celiac disease development. Fine mapping and deep resequencing of the regions, and functional characterization of the potential candidate genes, will be required to firmly establish the true causal genes and their role in the disease process.
METHODS
Subjects. Detailed characteristics of UKGWAS, IRISH and DUTCH samples are provided in Supplementary Table 1 online, and in our previously published study 2 . All subjects were of Northern European origin. UK2 subjects were recruited similarly to the previously described UKGWAS subjects 2 ; cases were recruited from hospital clinics and controls from the British 1958 Birth Cohort, except for 374 cases and 176 unrelated controls recruited directly through Celiac UK advertisement. For DNA procedures, see Supplementary Methods. We note that HLA-DQ2.5cis carriage rates (Supplementary Table 1 , inferred from rs2187668) were similarly high across the celiac collections (carriage rate 87.4-89.1%) and similarly low across the control populations (25.5-33.8%), suggesting broadly comparable phenotypic ascertainment across the four collections. We obtained informed consent from all subjects, and ethical approval from Oxfordshire Research Ethics Committee B or East London and the City Research Ethics Committee 1 (UKGWAS, UK2), the Medical Ethical Committee of the University Medical Center Utrecht (DUTCH) and the Institutional Ethics Committee of St. James's Hospital (IRISH).
Marker selection and genotyping. From our published genome-wide association study of celiac disease 2 with 310,605 post-quality control markers (HardyWeinberg equilibrium (HWE) P 4 0.0001 in controls), we selected single non-HLA SNPs with two-tailed allele count w 2 -test P o 0.00275, or P o 0.01, if nsSNPs. We performed genotyping using the GoldenGate assay (Illumina) and managed genotyping data and clustering of SNP genotypes in BeadStudio (Illumina). We excluded samples with o95% call rate over 1,025 SNPs, SNPs with o95% call rate over remaining samples and SNPs with poor amplification or poor genotype cloud clustering.
Quality-control steps. Using the 1,025 SNP dataset, we made pairwise comparisons of identity-by-descent for all samples (UKGWAS, UK2, IRISH and DUTCH) using PLINK 26 . We detected a higher proportion of first-degree relatives in this combined dataset (98 pairs) than in the initial UK celiac GWAS (11 pairs); therefore, in the current analyses, we excluded the lowest call rate sample from each pair of first-degree relatives from the entire study dataset. Minor but insignificant changes are therefore present in the UKGWAS dataset results compared to our previous publication 2 .
Potential ethnic outlier samples were excluded (n ¼ 3, outliers had previously been excluded from the UKGWAS dataset) using the nearest neighbor allele sharing method in PLINK (samples with Z scores o-3 with 41 of 5 nearest neighbors excluded). We applied a filter for SNP selection for follow-up GoldenGate genotyping based on HWE P 4 0.0001 in Infinium genotyped controls from the UKGWAS. HWE P values in each of the follow-up UK2, Irish and Dutch collections are shown in Supplementary Data 1. Because of the prior filter step, we did not specifically exclude any follow-up SNPs on the basis of HWE analysis. All of the top association findings were in HWE in controls.
Genotype statistical analysis. We carried out Cochran-Mantel-Haenszel allele count w 2 association tests using PLINK 26 with four clusters: UKGWAS (Infinium assay), UK2 (GoldenGate assay), Irish and Dutch collections. All P values are two-tailed. As we observed minimal evidence for bias in the Cochran-Mantel-Haenszel test statistics due to population stratification or other factors (l GC values r1.03), we present uncorrected statistics. To test for differences in association across the datasets as manifested by heterogeneity of odds ratios at disease-associated regions, we applied the Breslow-Day test to SNPs in Table 1 . We also evaluated these SNPs and HLA-DQ2.5cis (inferred by rs2187668 genotype) for possible epistatic (gene-gene) interaction in predisposing to celiac disease, as implemented in PLINK. We also tested for epistatic interactions using a second model 27 , implemented in R statistical software. For the PLINK analysis of interaction, genotypes at the SNPs are evaluated as allele 'doses' (for example, 0, 1 or 2), whereas for the second model, heterozygotes and homozygotes for the higher-risk allele are pooled together and compared against the lower-risk homozygote genotype. Both analyses tested for statistically significant departure from the model of log-additive odds ratios as evaluated by logistic regression.
We also investigated possible influence of stratification by an alternative principle components approach in which each dataset was separately evaluated by EIGENSTRAT software 28 . After eliminating SNPs in the nine regions showing association with celiac disease, we applied EIGENSTRAT to the remaining SNPs (drawn from 310,605 SNPs for UKGWAS, or from 1,025 SNPs for UK2, IRISH and DUTCH) to determine eigenvectors that correct for possible population stratification in cases and controls. For each case-control set, EIGENSTRAT calculates the Armitage trend test w 2 statistic for each genotyped SNP and then applies a SNP-specific correction on the basis of the eigenvectors that individually adjusts the Armitage w 2 value. Following EIGENSTRAT correction, we also corrected with the residual genomic control factor for each collection and then combined the post-correction w 2 values across the four studies according to a previously described meta-analysis method 29 . This enabled us to achieve corrected Z scores and P values for each SNP that could be compared to the Cochran-Mantel-Haenszel P values and showed that all nine regions remain significant at P o 5 Â10 À7 after correction by this alternative approach (Supplementary Data 1). The corrected P values for SNPs not in the nine celiac disease-associated regions also generate a Q-Q plot that shows no evidence of overdispersion and is almost identical to the Q-Q plot (Fig. 1b) of the Cochran-Mantel-Haenszel P values.
Calculation of familial clustering for each region is described in Supplementary Methods.
P-value threshold for genome-wide statistical significance. For statistical significance of disease association results in the combined genome scan (UKGWAS) and follow-up datasets (UK2, Dutch, Irish), we applied the same genome-wide significance threshold (P o 5 Â 10 À7 ) adopted by the WTCCC 7 . It should be noted that this threshold is close to the conservative Bonferronicorrected significance threshold suggested 3 for a two-stage study such as ours in which genome scan and subsequent results from stage 2 follow-up samples are combined. As 307,411 non-HLA SNPs were tested in our genome scan, the genome-wide significance threshold based on this criteria would be approximately 0.05/307,411, or 2 Â 10 À7 .
Whole-blood expression analysis. We collected PAXgene (PreAnalytiX) blood RNA samples from unselected Illumina Hap300 genotyped UKGWAS celiac disease cases. All subjects were selected on the basis of gluten-free diet treatment for 46 months to avoid possible bias in gene expression levels due to active inflammation. Notable features of this experimental design were: use of primary cells with minimal cell handling prior to RNA stabilization, analysis of expression from unstimulated leucocytes, and the possibility that the samples would be enriched for causal genetic variants compared to healthy controls. RNA was extracted using the PAXgene protocol, hybridized to Illumina HumanRef-8v2 expression arrays, scanned and processed in BeadStudio. Data were cubic spline normalized.
We obtained whole-blood PAXgene expression data from 114 individuals with celiac disease who had been genotyped in the UKGWAS. To assess the quality of the RNA for each sample, we assessed 6,298 genes with two different probes present on the Illumina HumanRef-8v2 array. We correlated intensities for all probes for each sample (median Pearson correlation for all samples ¼ 0.22) and removed two outlier samples that had low correlation (Pearson correlation o0.10). Analysis of transcripts mapping to the nonpseudoautosomal region of chromosome Y allowed us to determine sex, and we removed two samples with mismatched gender. We removed one further sample in which genotypes did not correlate as expected with the cis expression level across the genome. We analyzed data from 109 individuals after applying these quality control criteria. ANOVA tests were carried out to investigate possible cis effects of the strongest SNP associations on candidate gene expression from disease-associated regions.
Intestinal biopsy expression analysis. We collected duodenal tissue biopsies in RNAlater (Ambion). RNA was extracted using TRIzol (Invitrogen) and glass beads, hybridized to HumanRef-8v2 arrays and analyzed as for the PAXgene samples. Expression profiling of T-cell subsets is described in Supplementary Methods.
Note: Supplementary information is available on the Nature Genetics website.
